Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing presentation: reset

A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRASG12C inhibitor, in advanced solid tumors

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 1 of 1
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRASG12C inhibitor, in advanced solid tumors
Pasi A Jänne
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 1 of 1